Enhancing the anti-tumor effect of melphalan by prior administra

Details Enhancing the anti-tumor effect of melphalan by prior administra Enhancing the anti-tumor effect of melphalan by prior administra

1994-09-07

1996-06-04

Wityshyn, Michael G.

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Oxidoreductases

424 941, 4241461, 514564, A61K 3748, A61K 3750, A61K 31195, A61K 39395

Patent

active

055230849

ABSTRACT:
L-amino acid oxidase is utilized to reduce plasma level of large neutral amino acids to allow the opportunity of increased melphalan transport into tumors and melphalan is administered when the plasma level of L-amino acid oxidase is sufficiently low so the gain from increased transport outweighs the loss from L-amino acid oxidase-mediated metabolism of melphalan. Preferably anti L-amino acid oxidase antibody is administered intermediate the L-amino acid oxidase and melphalan administrations to deplete L-amino acid oxidase activity once the L-amino acid oxidase has caused the melphalan transport improving plasma level reduction of large neutral amino acids thereby to reduce or eliminate degrading of melphalan by L-amino acid oxidase.

REFERENCES:
patent: 4772632 (1988-09-01), Vistica
patent: 4997651 (1991-03-01), Poole et al.
patent: 5075108 (1991-12-01), McKenzie et al.
Moynihan, M. K. et al., "Proc of the Amer. Assn for Cancer Research," vol. 36, Mar. 1995, p. 374 abstract #2230.
Wellner, D., et al, Fed. Proc. 31, p. 921, abstract 4019 (1972).
Friedman, H. S., et al, Proceedings of the American Association for Cancer Research, vol. 32, p. 318 Abstract 1886 (Mar. 1991).
The Merck Index, 11th edition, pp. 68 and 914 (1989).
Wellner, D., et al, J. Biol. Chem. 235, #7 2013-2018 (1960).
Barlogie, B., et al, Blood, vol. 67, No. 5 (May), 1298-1301 (1986).
Groothuis, D. R., et al, Cancer Research 52, 5590-5596 (Oct. 1992).
Momma, S., et al, Proceedings of AACR, vol. 26, p. 357, abstract #1408 (Mar. 1985).
Sarosy, G., et al, J. Clin. Oncol., vol. 6, No. 11, 1768-1782 (Nov. 1988).
Bloom, H. J. G., et al, Int. J. Radiation Oncology Biol. Phys., vol. 8, 1083-1113 (1982).
Horowitz, M. E., J. of Clin. Oncol., vol. 6, No. 2, 308-314 (Feb. 1988).
Houghton, J. A., Cancer Treatment Reports, vol. 69, No. 1, 91-96 (Jan. 1985).
Vistica, D. T., Proceedings of AACR and ASCO, vol. 18, p. 26, abstract #104, 1977.
Cornford, E. M., et al, Cancer Research 52, 138-143 (Jan. 1992).
Friedman, H. S., Cancer Research 46, 224-228 (Jan. 1986).
Leff, R. S., et al, J. Clin. Oncol., vol. 4, No. 11, 1586-1591 (Nov. 1986).
Prichard, J., et al, Br. J. Cancer, 45, 86-94 (1982).
Vistica, D. T., et al, Cancer Letters, 6, 345-350 (1979).
Friedman, H. S., et al, Cancer Research 46, 2827-2833 (Jun. 1986).
Friedman, H. S., et al, Cancer Research 48, 4189-4195 (Aug. 1988).
Rich, J. N., et al, Proceedings of AACR, vol. 34, p. 299, abstract No. 1778, dated Mar. 1993 but mailed Apr. 13, 1994.
Goldenberg, G. J., et al, Cancer Research 30, 2285-2291 (Sep. 1970).
Goldenberg, G. J., et al, Cancer Research 37, 755-760 (Mar. 1977).
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, 1202-1208 (1975).

Affiliated with

Also associated with

Rating

Enhancing the anti-tumor effect of melphalan by prior administra does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enhancing the anti-tumor effect of melphalan by prior administra, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancing the anti-tumor effect of melphalan by prior administra will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-381721